Clinical Trial Update: Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial assesses durvalumab plus lenvatinib as first-line therapy for unresectable hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Lenvatinib (lenvatinib)

Snippet

Sponsor: Zhejiang University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN